Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota
- 1 December 2016
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 311 (6) , G1018-G1036
Abstract
Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) represent a major health burden in industrialized countries. Although alcohol abuse and nutrition play a central role in disease pathogenesis, preclinical models support a contribution of the gut microbiota to ALD and NAFLD. This review describes changes in the intestinal microbiota compositions related to ALD and NAFLD. Findings from in vitro, animal, and human studies are used to explain how intestinal pathology contributes to disease progression. This review summarizes the effects of untargeted microbiome modifications using antibiotics and probiotics on liver disease in animals and humans. While both affect humoral inflammation, regression of advanced liver disease or mortality has not been demonstrated. This review further describes products secreted by Lactobacillus- and microbiota-derived metabolites, such as fatty acids and antioxidants, that could be used for precision medicine in the treatment of liver disease. A better understanding of host-microbial interactions is allowing discovery of novel therapeutic targets in the gut microbiota, enabling new treatment options that restore the intestinal ecosystem precisely and influence liver disease. The modulation options of the gut microbiota and precision medicine employing the gut microbiota presented in this review have excellent prospects to improve treatment of liver disease.Keywords
Funding Information
- Swiss National Science Foundation (Schweizerische Nationalfonds) (P2SKP3_158649)
- HHS | National Institutes of Health (NIH) (R01 AA020703, U01 AA021856)
- Biomedical Laboratory Research and Development, VA Office of Research and Development (Biomedical Laboratory Research and Development Service of the VA Office of Research and Development) (I01BX002213)
This publication has 228 references indexed in Scilit:
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Lactobacillus rhamnosus GG Treatment Potentiates Intestinal Hypoxia-Inducible Factor, Promotes Intestinal Integrity and Ameliorates Alcohol-Induced Liver InjuryThe American Journal of Pathology, 2011
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trialHepatology, 2011
- The Microbiome and Butyrate Regulate Energy Metabolism and Autophagy in the Mammalian ColonCell Metabolism, 2011
- Enteric dysbiosis associated with a mouse model of alcoholic liver diseaseHepatology, 2010
- Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitisAlcohol, 2009
- Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot studyAlcohol, 2008
- Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cellsJournal of Hepatology, 2008
- Fructose consumption as a risk factor for non-alcoholic fatty liver diseaseJournal of Hepatology, 2008
- Soluble Proteins Produced by Probiotic Bacteria Regulate Intestinal Epithelial Cell Survival and GrowthGastroenterology, 2007